JP2020518287A - 組み換え修飾された繊維芽細胞成長因子及びその治療用途 - Google Patents

組み換え修飾された繊維芽細胞成長因子及びその治療用途 Download PDF

Info

Publication number
JP2020518287A
JP2020518287A JP2020511867A JP2020511867A JP2020518287A JP 2020518287 A JP2020518287 A JP 2020518287A JP 2020511867 A JP2020511867 A JP 2020511867A JP 2020511867 A JP2020511867 A JP 2020511867A JP 2020518287 A JP2020518287 A JP 2020518287A
Authority
JP
Japan
Prior art keywords
polypeptide
modified fgf
corneal
recombinant modified
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020511867A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020518287A5 (https=
Inventor
エベリス，デイビッド
ジェンキンス−エベリス，ジェニファー
サブラマニアム，アムサカナン
ブラッドショー，ラルフ
Original Assignee
トレフォイル セラピューティクス，インク．
トレフォイル セラピューティクス，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トレフォイル セラピューティクス，インク．, トレフォイル セラピューティクス，インク． filed Critical トレフォイル セラピューティクス，インク．
Publication of JP2020518287A publication Critical patent/JP2020518287A/ja
Publication of JP2020518287A5 publication Critical patent/JP2020518287A5/ja
Priority to JP2024075396A priority Critical patent/JP2024112824A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020511867A 2017-05-05 2018-05-04 組み換え修飾された繊維芽細胞成長因子及びその治療用途 Pending JP2020518287A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024075396A JP2024112824A (ja) 2017-05-05 2024-05-07 組み換え修飾された繊維芽細胞成長因子及びその治療用途

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762502540P 2017-05-05 2017-05-05
US201762502529P 2017-05-05 2017-05-05
US62/502,540 2017-05-05
US62/502,529 2017-05-05
US201762584624P 2017-11-10 2017-11-10
US62/584,624 2017-11-10
PCT/US2018/031189 WO2018204847A2 (en) 2017-05-05 2018-05-04 Recombinant modified fibroblast growth factors and therapeutic uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024075396A Division JP2024112824A (ja) 2017-05-05 2024-05-07 組み換え修飾された繊維芽細胞成長因子及びその治療用途

Publications (2)

Publication Number Publication Date
JP2020518287A true JP2020518287A (ja) 2020-06-25
JP2020518287A5 JP2020518287A5 (https=) 2021-06-17

Family

ID=64016756

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020511867A Pending JP2020518287A (ja) 2017-05-05 2018-05-04 組み換え修飾された繊維芽細胞成長因子及びその治療用途
JP2024075396A Pending JP2024112824A (ja) 2017-05-05 2024-05-07 組み換え修飾された繊維芽細胞成長因子及びその治療用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024075396A Pending JP2024112824A (ja) 2017-05-05 2024-05-07 組み換え修飾された繊維芽細胞成長因子及びその治療用途

Country Status (12)

Country Link
US (2) US11479591B2 (https=)
EP (2) EP4621067A3 (https=)
JP (2) JP2020518287A (https=)
KR (1) KR20200078425A (https=)
CN (1) CN111148755A (https=)
AU (1) AU2018261021B2 (https=)
BR (1) BR112019023260A2 (https=)
CA (1) CA3062473A1 (https=)
DK (1) DK3619324T3 (https=)
ES (1) ES3041527T3 (https=)
MX (1) MX2019013210A (https=)
WO (1) WO2018204847A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023532046A (ja) * 2020-06-26 2023-07-26 トレフォイル セラピューティクス，インク． 組換え修飾線維芽細胞増殖因子およびそれを使用した治療

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019013210A (es) 2017-05-05 2020-07-20 Trefoil Therapeutics Inc Factores de crecimiento recombinantes modificados de fibroblastos y usos terapéuticos de los mismos.
WO2021261946A1 (ko) 2020-06-26 2021-12-30 엘티소재주식회사 헤테로고리 화합물 및 이를 이용한 유기 발광 소자
EP4574211A3 (en) * 2021-05-14 2025-09-10 Claris Biotherapeutics, Inc. Compositions of growth factor for the treatment of eye disease
CN113289005B (zh) * 2021-07-06 2022-05-31 温州医科大学 rhFGF-21在制备治疗干眼症药物中的应用
WO2023019218A1 (en) * 2021-08-12 2023-02-16 Trefoil Therapeutics, Inc. Modified fibroblast growth factors for treating fibrotic diseases
US12357843B2 (en) 2022-03-25 2025-07-15 Cutera, Inc. Methods of skin treatment with laser light
CN115177717B (zh) * 2022-08-31 2026-02-06 贵州医科大学附属医院 一种治疗眼表及角膜上皮疾病的药物

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001519142A (ja) * 1997-10-03 2001-10-23 アムジエン・インコーポレーテツド 肝細胞増殖活性を有する線維芽細胞増殖因子
JP2004517607A (ja) * 2000-08-15 2004-06-17 ファージ バイオテクノロジー コーポレイション 生物学的に活性なヒト酸性線維芽細胞成長因子の産生方法および血管新生の促進におけるその使用
JP2007535306A (ja) * 2003-12-10 2007-12-06 イーライ リリー アンド カンパニー 線維芽細胞成長因子２１の突然変異タンパク質
JP2014534172A (ja) * 2011-09-26 2014-12-18 ノバルティス アーゲー 代謝障害を処置するための融合タンパク質
WO2015048188A2 (en) * 2013-09-25 2015-04-02 Trefoil Therapeutics, Llc Modified fibroblast growth factors for the treatment of ocular disorders
WO2015198175A1 (en) * 2014-06-27 2015-12-30 Florida State University Research Foundation, Inc. Design of fgf-1 mutants to effectively eliminate reactive cysteine residues
WO2017026156A1 (ja) * 2015-08-13 2017-02-16 富士フイルム株式会社 多能性幹細胞の培養方法、培養容器の製造方法、培養容器、及び細胞培養用の足場材料

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022758A (en) 1973-06-19 1977-05-10 Ab Kabi Isolation of coagulation factors I and VIII from biological material
US5552528A (en) * 1986-03-03 1996-09-03 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bovine b-endothelial cell growth factor
US5312911A (en) 1987-10-22 1994-05-17 Merck & Co., Inc. Cysteine-modified acidic fibroblast growth factor
US5223483A (en) 1987-10-22 1993-06-29 Merck & Co., Inc. Cysteine-modified acidic fibroblast growth factor
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5510329A (en) 1988-04-26 1996-04-23 Ramot University For Applied Research And Industrial Development Ltd. Preparations for the treatment of eyes
GB2223496B (en) * 1988-08-08 1992-05-27 British Bio Technology Synthetic gene encoding mature human acid fibroblast growth factor
US6780837B1 (en) 1989-08-30 2004-08-24 The Regents Of The University Of California Prevention of retinal injury and degeneration by specific factors
US5124154A (en) 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5624893A (en) 1993-10-14 1997-04-29 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation
GB9523946D0 (en) 1995-11-23 1996-01-24 Bayer Ag Leukotriene antagonistic benzoic acid derivatives
US20040071787A1 (en) 1996-05-01 2004-04-15 Maine Medical Center Research Institute Pharmacologic, therapeutic and diagnostic regulation of FGF-1 export
WO1999055861A2 (en) 1998-04-28 1999-11-04 Eisai Co., Ltd. Fibroblast growth factor mutein compositions and methods of use therefor
WO2001038357A2 (en) * 1999-11-22 2001-05-31 Millennium Pharmaceuticals, Inc. Jaffa, a novel fibroblast growth factor family member and uses therefor
US20020001825A1 (en) 2000-03-31 2002-01-03 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
US20100254900A1 (en) 2002-03-18 2010-10-07 Campbell Phil G Biocompatible polymers and Methods of use
WO2005048942A2 (en) 2003-11-13 2005-06-02 Pharmacia Corporation Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent
US7790682B1 (en) 2003-12-02 2010-09-07 The Florida State University Research Foundation, Inc. Engineered human acidic fibroblast growth factors and associated methods
EP1634877B1 (en) * 2004-08-17 2011-06-22 Simpson Biotech Co., Ltd. Mixture and compounds from mycelia of antrodia camphorata and use thereof
US8541413B2 (en) 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
US20090156477A1 (en) 2005-03-29 2009-06-18 Massachusetts Institute Of Technology Compositions and Methods for Regulating Inflammatory Responses
US7767656B2 (en) 2005-04-25 2010-08-03 Molly S Shoichet Blends of temperature sensitive and anionic polymers for drug delivery
CN100334114C (zh) 2005-07-22 2007-08-29 彭隽 一种新型融合蛋白及其制备
AU2007240732B2 (en) 2006-04-21 2013-07-04 Amgen, Inc. Buffering agents for biopharmaceutical formulations
AR062069A1 (es) 2006-07-14 2008-10-15 Genentech Inc Replegado de proteinas recombinantes
EP2049144B8 (en) 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylation of peptides via o-linked glycosylation sequences
US7776825B1 (en) 2006-11-09 2010-08-17 Florida State University Research Foundation, Incorporated Mutant polypeptides of fibroblast growth factor 1
US7659379B1 (en) 2007-05-24 2010-02-09 Florida State University Research Foundation, Inc. Mutants of human fibroblast growth factor having increased stability and/or mitogenic potency
KR20200075044A (ko) * 2008-01-22 2020-06-25 아라임 파마슈티칼즈, 인크. 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
US8461111B2 (en) 2009-05-20 2013-06-11 Florida State University Research Foundation Fibroblast growth factor mutants having improved functional half-life and methods of their use
US20110224404A1 (en) 2010-03-11 2011-09-15 Florida State University Research Foundation Method for development of a peptide building block useful for de novo protein design
WO2011130729A2 (en) 2010-04-16 2011-10-20 Salk Institute For Biological Studies Methods for treating metabolic disorders using fgf
US9029113B2 (en) 2011-03-11 2015-05-12 Kaneka Corporation Modified aminotransferase, gene thereof, and method for producing optically active amino compound using same
WO2013036708A2 (en) 2011-09-07 2013-03-14 The Regents Of The University Of California Compositions and methods for tissue repair with extracellular matrices
US20140045751A1 (en) 2012-08-10 2014-02-13 Florida State University Research Foundation Recombinant human fibroblast growth factor-1 as a novel therapeutic for ischemic diseases and methods thereof
CN113679699B (zh) 2012-09-12 2022-10-28 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
US9714291B2 (en) 2012-10-05 2017-07-25 Kyowa Hakko Kirin Co., Ltd Heterodimer protein composition
US20150253308A1 (en) * 2013-05-03 2015-09-10 Orasis Compositions and methods of treating glaucoma
TWI634898B (zh) * 2013-10-07 2018-09-11 雅祥生技醫藥股份有限公司 經修飾之人類酸性纖維母細胞生長因子及其組合物
US20150104494A1 (en) * 2013-10-11 2015-04-16 Ohio State Innovation Foundation Methods for repair of ear canal tissue defects
AU2014340241B2 (en) 2013-10-21 2018-11-01 Salk Institute For Biological Studies Mutated fibroblast growth factor (FGF) 1 and methods of use
WO2015061351A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
AU2016252426A1 (en) 2015-04-20 2017-11-23 Salk Institute For Biological Studies Fibroblast growth factor (FGF) 1 mutants and methods of use to reduce blood glucose
EP3285798A4 (en) 2015-04-20 2018-12-05 Salk Institute for Biological Studies Fibroblast growth factor (fgf) 1 with mutation in the heparin binding domain and methods of use to reduce blood glucose
EP3368059A4 (en) 2015-10-30 2019-03-27 Salk Institute for Biological Studies TREATMENT OF STEROID-INDUCED HYPERGLYCEMIA WITH FIBROBLAST GROWTH FACTOR (FGF) -1 ANALOGUE
CN108718522A (zh) 2016-02-23 2018-10-30 赛森生物股份有限公司 Il-6拮抗剂制剂及其用途
WO2017172525A2 (en) 2016-03-28 2017-10-05 Trefoil Therapeutics, Llc Modified fibroblast growth factors and uses thereof
MX2019013210A (es) 2017-05-05 2020-07-20 Trefoil Therapeutics Inc Factores de crecimiento recombinantes modificados de fibroblastos y usos terapéuticos de los mismos.
CN111315886A (zh) 2017-06-23 2020-06-19 珠海亿胜生物制药有限公司 重组人碱性成纤维细胞生长因子(rh-bFGF)以及包含rh-bFGF的药物组合物
DK4364724T3 (da) 2018-05-10 2025-12-22 Regeneron Pharma Formuleringer med høj koncentration af VEGF-receptorfusionsprotein
CN116710568A (zh) 2020-06-26 2023-09-05 特里福伊尔治疗公司 重组修饰成纤维细胞生长因子及其治疗用途
WO2023019218A1 (en) 2021-08-12 2023-02-16 Trefoil Therapeutics, Inc. Modified fibroblast growth factors for treating fibrotic diseases
WO2023043743A1 (en) 2021-09-14 2023-03-23 Trefoil Therapeutics, Inc. Methods of treatment using modified fgf-1 polypeptides

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001519142A (ja) * 1997-10-03 2001-10-23 アムジエン・インコーポレーテツド 肝細胞増殖活性を有する線維芽細胞増殖因子
JP2004517607A (ja) * 2000-08-15 2004-06-17 ファージ バイオテクノロジー コーポレイション 生物学的に活性なヒト酸性線維芽細胞成長因子の産生方法および血管新生の促進におけるその使用
JP2007535306A (ja) * 2003-12-10 2007-12-06 イーライ リリー アンド カンパニー 線維芽細胞成長因子２１の突然変異タンパク質
JP2014534172A (ja) * 2011-09-26 2014-12-18 ノバルティス アーゲー 代謝障害を処置するための融合タンパク質
WO2015048188A2 (en) * 2013-09-25 2015-04-02 Trefoil Therapeutics, Llc Modified fibroblast growth factors for the treatment of ocular disorders
WO2015198175A1 (en) * 2014-06-27 2015-12-30 Florida State University Research Foundation, Inc. Design of fgf-1 mutants to effectively eliminate reactive cysteine residues
WO2017026156A1 (ja) * 2015-08-13 2017-02-16 富士フイルム株式会社 多能性幹細胞の培養方法、培養容器の製造方法、培養容器、及び細胞培養用の足場材料

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"pET-21a-d(+) Vectors", NOVAGEN社カタログ, JPN7022001092, 31 December 1998 (1998-12-31), ISSN: 0005363836 *
HIREL, P. H. ET AL.: "Extent of N-terminal methionine excision from Escherichia coli proteins is governed by the side-chai", PNAS, vol. 86, no. 21, JPN6023028769, 1989, pages 824 - 8251, ISSN: 0005363834 *
東端 啓貴: "生物工学基礎講座 バイオよもやま話 大腸菌を宿主とした異種タンパク質高発現のイロハ", 生物工学, vol. 91, no. 2, JPN6023028768, 2013, pages 96 - 100, ISSN: 0005363835 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023532046A (ja) * 2020-06-26 2023-07-26 トレフォイル セラピューティクス，インク． 組換え修飾線維芽細胞増殖因子およびそれを使用した治療

Also Published As

Publication number Publication date
US20200190158A1 (en) 2020-06-18
US11479591B2 (en) 2022-10-25
RU2019139358A (ru) 2021-06-07
EP3619324B1 (en) 2025-07-09
MX2019013210A (es) 2020-07-20
US12600756B2 (en) 2026-04-14
KR20200078425A (ko) 2020-07-01
BR112019023260A2 (pt) 2022-02-22
AU2018261021A1 (en) 2019-12-12
EP4621067A3 (en) 2025-11-19
EP3619324A4 (en) 2020-12-30
RU2019139358A3 (https=) 2021-08-26
AU2018261021B2 (en) 2024-09-12
EP4621067A2 (en) 2025-09-24
US20230130851A1 (en) 2023-04-27
ES3041527T3 (en) 2025-11-12
JP2024112824A (ja) 2024-08-21
DK3619324T3 (da) 2025-09-22
EP3619324A2 (en) 2020-03-11
CA3062473A1 (en) 2018-11-08
WO2018204847A2 (en) 2018-11-08
CN111148755A (zh) 2020-05-12

Similar Documents

Publication Publication Date Title
US12600756B2 (en) Recombinant modified fibroblast growth factors and therapeutic uses thereof
Grisanti et al. Decorin modulates wound healing in experimental glaucoma filtration surgery: a pilot study
JP7759693B2 (ja) モンテルカストおよびペプチドの新規接合体
JP6868014B2 (ja) 翼状片を治療するための組成物及び方法
US20240024421A1 (en) Recombinant modified fibroblast growth factors and therapeutic uses thereof
US20210338777A1 (en) Modified fibroblast growth factors for the treatment of ocular disorders
KR20220079860A (ko) 신규 펩티드
AU2016326750B2 (en) Viral conjunctivitis treatment using ranpirnase and/or amphinase
CN101252949A (zh) 促进上皮再生
JP2023503374A (ja) 新規なペプチドと多糖類とのコンジュゲート
CN101972224B (zh) 一种眼用原位凝胶
RU2811435C2 (ru) Рекомбинантные модифицированные факторы роста фибробластов и их терапевтическое применение
JP2022516729A (ja) ロイコトリエン受容体アンタゴニストを含有する新たな製剤
CN101537172A (zh) 一种含有重组人角质细胞生长因子-2滴眼液及其制备方法
HK40019822B (en) Recombinant modified fibroblast growth factors and therapeutic uses thereof
HK40019822A (en) Recombinant modified fibroblast growth factors and therapeutic uses thereof
WO2017172525A2 (en) Modified fibroblast growth factors and uses thereof
RU2733392C1 (ru) Комбинированное офтальмологическое средство
HK40030921A (en) Modified fibroblast growth factors-1 for the treatment of ocular disorders
US20140235545A1 (en) The use of HCV immunogenic peptide or a derivative thereof in the prevention or treatment of arthritis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210429

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210430

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220314

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230405

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20230523

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230712

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240507

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240621

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240705